Swiss company Vifor Pharma and Germany’s Evotec AG launched a joint venture to focus on the discovery and development of new therapies for kidney diseases.
Daiichi Sankyo is taking Seattle Genetics to court over the technology the two companies used to develop antibody-drug conjugates (ADCs) during a partnership that spanned seven years.
Biogen Inc. revived plans to seek U.S. approval for the experimental Alzheimer’s treatment aducanumab, surprising investors.
Cambridge, Mass.-based bluebird bio and Bagsvaerd, Denmark-based Novo Nordisk agreed to develop next-generation genome editing therapies for genetic diseases, including hemophilia.
W2O – a leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector – acquired Arcus Medica, a recognized leader in medical and scientific communications.
Leeds, UK-based 4D Pharma and Merck/MSD are developing Live Biotherapeutics vaccines, a new class of medicines.
Less than one month after filing for bankruptcy, uBiome is shutting the Bay Area microbiome company’s doors and selling off assets.
Lexicon Pharmaceuticals Inc. said France’s Sanofi SA will pay the Texas-based drugmaker $260 million for the termination of their partnership to develop the diabetes drug Zynquista.
Cognoa and Eversana announce partnership to advance commercialization standard for prescription digital medicines
Cognoa and Eversana announced a partnership to advance the industry standard by which digital medicines will be ordered, dispensed, and covered by insurance.
Boston-based venture capital firm Vida Ventures raised $600 million for the new, oversubscribed life science fund Vida Ventures II.